Frequently Asked Questions About Inositol
What is the difference between myo-inositol and D-chiro-inositol?
Myo-inositol (MI) and D-chiro-inositol (DCI) are two of the nine naturally occurring stereoisomers of inositol. They serve different roles in the body’s insulin signaling cascade.
Myo-inositol is the predominant form, comprising over 99% of the inositol in most tissues. It acts as a second messenger in the insulin signaling pathway and plays a role in FSH (follicle-stimulating hormone) signaling in the ovaries. The vast majority of clinical research on inositol uses myo-inositol, particularly the PCOS and fertility literature.
D-chiro-inositol is present in much smaller quantities and is produced from myo-inositol by an epimerase enzyme. It mediates the non-oxidative storage of glucose as glycogen. In women with PCOS, this conversion process appears to be impaired in some tissues.
The 40:1 ratio of myo-inositol to D-chiro-inositol reflects the natural physiological ratio in the body and is the most studied combination for PCOS. Several randomized trials support this ratio for improving ovulation, oocyte quality, and metabolic parameters (Nordio & Proietti, 2012, Unfer et al., 2017). Taking excessive DCI alone may actually impair oocyte quality, so the ratio matters.
Does inositol help with PCOS?
Inositol, particularly myo-inositol, has some of the strongest evidence of any supplement for PCOS management. Multiple randomized controlled trials demonstrate improvements across several PCOS-related endpoints.
For ovulation and fertility: myo-inositol (4 g/day) has been shown to restore ovulatory cycles in anovulatory women with PCOS and improve oocyte quality during IVF cycles (Papaleo et al., 2007). A meta-analysis found that myo-inositol increased clinical pregnancy rates and reduced the amount of gonadotropins needed during IVF (Unfer et al., 2016).
For metabolic parameters: inositol improves insulin sensitivity, reduces fasting insulin levels, and lowers androgen levels (testosterone, DHEA-S) in women with PCOS. These hormonal improvements are the mechanism behind the menstrual cycle regulation.
In some trials, myo-inositol has shown comparable efficacy to metformin for insulin sensitization in PCOS, with fewer gastrointestinal side effects (Pkhaladze et al., 2021). It is not a replacement for metformin or other prescribed treatments but is increasingly recognized as a complementary approach in PCOS management guidelines.
What are the side effects of inositol?
Inositol has a notably mild side effect profile. At standard doses (2-4 g/day of myo-inositol), side effects are uncommon. When they occur, they are typically gastrointestinal: nausea, gas, loose stools, or mild stomach discomfort. These effects are dose-dependent and usually resolve as the body adjusts.
At higher doses (12-18 g/day, as used in some anxiety and OCD studies), gastrointestinal side effects become more common. Diarrhea is the most frequently reported issue at these doses, affecting roughly 10-15% of participants in clinical trials (Levine, 1997).
Inositol does not cause weight gain, drowsiness, or sexual dysfunction, which distinguishes it from many pharmaceutical alternatives for anxiety and PCOS. There are no known withdrawal effects from discontinuation, and it does not appear to interact with hepatic drug metabolism enzymes in a clinically significant manner.
Is inositol safe during pregnancy?
Myo-inositol has been studied specifically in pregnant women and has demonstrated a favorable safety profile. Several randomized controlled trials have administered 4 g/day of myo-inositol throughout pregnancy, primarily to assess its role in preventing gestational diabetes mellitus (GDM).
A meta-analysis of these trials found that myo-inositol supplementation during pregnancy significantly reduced the incidence of GDM in women at high risk, with no increase in adverse maternal or neonatal outcomes (Crawford et al., 2015). The Italian Society of Obstetrics and Gynecology (SIGO) has included myo-inositol in its guidelines for GDM prevention.
Inositol is also naturally present in breast milk and in prenatal vitamins. However, as with all supplements during pregnancy, supplementation should be discussed with your healthcare provider, particularly regarding appropriate dosing and form.
Does inositol help with anxiety?
Yes, though the evidence comes primarily from studies using much higher doses than those used for PCOS. In double-blind controlled trials, myo-inositol at 12-18 g/day has shown efficacy comparable to fluvoxamine (an SSRI) for panic disorder, with fewer side effects (Benjamin et al., 1995). Significant reductions in panic attack frequency and severity of agoraphobia were observed.
For general anxiety and OCD, results are more mixed. A controlled trial found 18 g/day of inositol superior to placebo for OCD, but a subsequent trial combining inositol with SSRIs found no additional benefit (Fux et al., 1996).
The mechanism is thought to involve inositol’s role in the phosphatidylinositol (PI) cycle, which mediates serotonin receptor signaling. Low levels of inositol have been found in the cerebrospinal fluid of individuals with depression and impulsive behavior.
The main practical barrier is the dose: 12-18 g/day of powder is a substantial amount to take daily. At the lower doses used for PCOS (2-4 g/day), the anxiolytic effect is less well established.
How long does it take for inositol to work?
The timeline varies by condition and outcome:
PCOS / menstrual regulation: Improvements in menstrual cycle regularity and hormonal profiles (reduced testosterone, improved insulin sensitivity) typically emerge at 3-6 months of consistent supplementation. Ovulation restoration may occur within 1-3 months in some women.
Anxiety / panic disorder: In clinical trials using 12-18 g/day, significant reductions in panic attack frequency were observed by week 4, with continued improvement through week 8 (Benjamin et al., 1995).
Fertility / IVF outcomes: Trials typically administer inositol for 2-3 months prior to IVF cycle initiation to allow time for oocyte quality improvement.
As with most supplements, inositol is not a rapid-acting intervention. Setting expectations for a 2-3 month minimum trial period before evaluating results is appropriate for most applications.
Can I take inositol with other supplements or medications?
Inositol is generally compatible with most supplements and medications, but a few interactions warrant attention.
With metformin: Inositol and metformin both improve insulin sensitivity. Some clinicians use them together for PCOS, but this should be medically supervised to avoid hypoglycemia, though the risk is low with standard doses of either.
With SSRIs: Inositol has been studied alongside SSRIs for OCD with no adverse interactions, though the combination did not provide additional benefit beyond the SSRI alone in controlled trials (Fux et al., 1999).
With lithium: Lithium inhibits inositol monophosphatase, which is thought to be part of its mechanism of action. Supplemental inositol could theoretically interfere with lithium’s therapeutic effect. If you take lithium, consult your psychiatrist before supplementing with inositol.
Inositol is compatible with most vitamins, minerals, omega-3s, and common supplements without known interactions.
Does inositol affect blood sugar?
Yes, and this is one of its primary mechanisms of benefit. Myo-inositol is a second messenger in the insulin signaling pathway, and supplementation has been shown to improve insulin sensitivity in multiple populations.
In women with PCOS, 4 g/day of myo-inositol reduces fasting insulin and HOMA-IR (a measure of insulin resistance) (Genazzani et al., 2008). In pregnant women at risk of gestational diabetes, myo-inositol supplementation reduces fasting glucose and insulin levels.
Inositol does not cause hypoglycemia in healthy individuals at standard doses. It improves the efficiency of insulin signaling rather than acting as an insulin secretagogue. In people with normal insulin sensitivity and blood sugar, inositol supplementation produces minimal changes in glucose parameters. The effect is most pronounced in insulin-resistant individuals.
References
-
Unfer V, et al. Myo-inositol and D-chiro-inositol in PCOS treatment. Gynecol Endocrinol. 2017,33(7):571-577. PMID: 28944956
-
Papaleo E, et al. Myo-inositol in patients with polycystic ovary syndrome. Hum Reprod. 2007,22(5):1547-1553. PMID: 17364286
-
Unfer V, et al. Myo-inositol effects in women with PCOS: a meta-analysis. Reprod Biomed Online. 2016,33(6):719-730. PMID: 27568692
-
Pkhaladze L, et al. Myo-inositol vs metformin in adolescent girls with PCOS. Int J Endocrinol. 2021,2021:6614781. PMID: 33607657
-
Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997,7(2):147-155. PMID: 9169302
-
Crawford TJ, et al. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev. 2015,12:CD011507. PMID: 26678431
-
Benjamin J, et al. Inositol treatment for panic disorder. Am J Psychiatry. 1995,152(7):1084-1086. PMID: 7726322
-
Fux M, et al. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 1996,153(9):1219-1221. PMID: 8780431
-
Fux M, et al. Inositol augmentation of SSRI for OCD. Int J Neuropsychopharmacol. 1999,2(3):193-195. PMID: 10468315
-
Genazzani AD, et al. Myo-inositol administration improves endocrine parameters in PCOS. Gynecol Endocrinol. 2008,24(3):139-144. PMID: 18854115